APP

Amyloid-beta precursor protein · P05067 · APP on Sugi Atlas →

361,424 patent compounds predicted against APP, 226,080 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL38731)	0.97	15/20
SCHEMBL8066	1.00	13/20
SCHEMBL8067	0.65	13/20
Hydrochloric Acid (SCHEMBL39765)	0.71	11/20
Curcumin (SCHEMBL8440)	1.00	10/20
Curcumin (SCHEMBL8441)	1.00	10/20
Curcumin (SCHEMBL40025)	0.94	10/20
Furosemide (SCHEMBL9811)	0.77	9/20
Edaravone (SCHEMBL4704)	0.81	8/20
SCHEMBL29787	0.51	8/20
Lucanthone (SCHEMBL9156)	1.00	7/20
SCHEMBL34413	0.57	7/20
Quercetin (SCHEMBL19723)	1.00	6/20
Dithiazanine (SCHEMBL22877)	0.92	6/20
SCHEMBL32075	0.67	6/20
SCHEMBL22562	0.61	6/20
SCHEMBL40748	0.59	6/20
SCHEMBL31945	0.49	6/20
Kaempferol (SCHEMBL18817)	1.00	5/20
Myricetin (SCHEMBL19302)	1.00	5/20

Clinical trials — most relevant to APP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)	PHASE4	COMPLETED
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	PHASE2/PHASE3	RECRUITING
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.	PHASE2/PHASE3	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	PHASE2/PHASE3	RECRUITING
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)	PHASE2	COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)	PHASE2	ACTIVE_NOT_RECRUITING
Pharmacological Enhancement of Glymphatic Function in Humans	PHASE1/PHASE2	COMPLETED
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY	PHASE1	COMPLETED
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease	PHASE1	COMPLETED
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease	PHASE1	COMPLETED
Exploratory and Safety Study of [F-18]W372	EARLY_PHASE1	COMPLETED
An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease	nan	COMPLETED
Dominantly Inherited Alzheimer Network (DIAN)	nan	RECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients	nan	COMPLETED
tACS for Amyloid-β Reduction in Alzheimer's Disease	nan	COMPLETED
Clearance Mechanisms in Atypical Neurodegenerative Diseases	nan	UNKNOWN
Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers	nan	UNKNOWN
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease	nan	COMPLETED
Central and Systemic Inflammation in Alzheimer's Disease	nan	COMPLETED
Perioperative Research Into Memory, Genomics in the Intensive Therapy Unit: Alzheimer's	nan	UNKNOWN
Epilepsy in Alzheimer's Disease: Effect on Disease Progression	nan	UNKNOWN
EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES	nan	ENROLLING_BY_INVITATION
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants	nan	COMPLETED
Late Onset Alzheimer's Disease	nan	RECRUITING
The Genetic Characterization of Dementia	nan	COMPLETED
New Biomarker for Alzheimer's Disease Diagnostic	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a APP binder may also engage these)

Protein	Name	Similarity
P12023	—	1.000	P12023 →
P08592	—	1.000	P08592 →
P79307	—	1.000	P79307 →
Q5IS80	—	1.000	Q5IS80 →
Q60495	—	1.000	Q60495 →
P53601	—	1.000	P53601 →
Q95241	—	1.000	Q95241 →
O73683	—	1.000	O73683 →
O93279	—	0.998	O93279 →
Q06481	—	0.993	Q06481 →
P15943	—	0.992	P15943 →
Q06335	—	0.991	Q06335 →
A6QLD2	—	0.982	A6QLD2 →
O18738	—	0.982	O18738 →
A5D794	—	0.982	A5D794 →
P36233	—	0.981	P36233 →
Q16625	—	0.981	Q16625 →
Q3V1G4	—	0.981	Q3V1G4 →
O70367	—	0.981	O70367 →
Q61137	—	0.980	Q61137 →
A2WNF5	—	0.980	A2WNF5 →
O14525	—	0.980	O14525 →
Q9TSZ6	—	0.980	Q9TSZ6 →
Q28685	—	0.980	Q28685 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.980	landscape →
Q5NBP9	—	0.979	Q5NBP9 →
Q05764	—	0.979	Q05764 →
Q5EGE1	—	0.979	Q5EGE1 →
Q9W7R4	—	0.979	Q9W7R4 →
Q9PUU8	—	0.979	Q9PUU8 →